[Skip to Content]
[Skip to Content Landing]
Comment & Response
June 4, 2014

Guidelines for Cardiovascular Risk Assessment and Cholesterol Treatment—Reply

Author Affiliations
  • 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota
JAMA. 2014;311(21):2236. doi:10.1001/jama.2014.4078

In Reply We agree with Dr Lloyd-Jones and colleagues that the ACC/AHA cholesterol guidelines1,2 represent progress by redirecting the focus from reducing low-density lipoprotein cholesterol levels to reducing cardiovascular risk and by promoting personalized decisions about statin use. Although the guideline literally recommends “Initiation of statin therapy for patients who are eligible for primary CVD prevention and have a predicted 10-year hard AS[atherosclerotic]CVD risk of ≥7.5%,”2(p36,Table) our Viewpoint advocated for inviting at-risk patients to engage in shared decision making about statins to reduce their risk for ASCVD.

First Page Preview View Large
First page PDF preview
First page PDF preview